蔚藍生物(603739.SH):陳剛減持11.46萬股 股東及董監高提前終止減持計劃
格隆匯5月15日丨蔚藍生物(603739.SH)公佈,截至本公告披露日,公司董事、總經理陳剛已通過集中競價交易方式減持公司股份累計11.46萬股,佔公司總股本的0.0741%。股東北京康煜、監事原蕊女士未實施減持。2020年5月15日,公司收到陳剛、北京康煜、原蕊《關於提前終止減持蔚藍生物股份計劃的告知函》,基於對公司價值的合理判斷,經綜合考慮,陳剛、北京康煜、原蕊決定提前終止本次減持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.